Drug Profile
Lintuzumab Bi-213
Alternative Names: Anti-CD33 monoclonal antibody M195 Bi-213; Bi213 MOAB M195; Bi213 monoclonal antibody M195; Bismab-A; Bismuth-213 HuM195; Bismuth-213 lintuzumab; Bismuth-213-labelled HuM195; HuM195-Bi-213; Lintuzumab bismuth-213; Monoclonal antibody M195 Bi-213 conjugate; Monoclonal antibody M195 bismuth-213; SMART M195 bismuth-213Latest Information Update: 24 Apr 2019
Price :
$50
*
At a glance
- Originator PDL BioPharma
- Developer Actinium Pharmaceuticals
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action CD33 antigen inhibitors; Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acute myeloid leukaemia